_PRIVATE_LIMITED.webp)
Histogenetics (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 0.10 M
- Company Age 18 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 3.18%
- Profit Growth 27.71%
- Ebitda 33.99%
- Net Worth 16.02%
- Total Assets -28.01%
About Histogenetics (India)
Histogenetics (India) Private Limited (HIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 18 December 2006 and has a history of 18 years and two months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Soo Lee, Nezih Cereb, and Nagarajan serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U72900TN2006PTC061761
- Company No.
061761
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Dec 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Histogenetics (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagarajan  | Director | 06-Jun-2016 | Current |
Soo Lee  | Director | 18-Dec-2006 | Current |
| Nezih Cereb | Director | 18-Dec-2006 | Current |
Financial Performance of Histogenetics (India).
Histogenetics (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.18% increase. The company also saw a substantial improvement in profitability, with a 27.71% increase in profit. The company's net worth Soared by an impressive increase of 16.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Histogenetics (India)?
Unlock access to Histogenetics (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Datri Blood Stem Cell Donors RegistrySoo Lee, Nezih Cereb and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Histogenetics (India)?
Histogenetics (India) has a workforce of 42 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Histogenetics (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Histogenetics (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
